STAT February 2, 2024
Usha Lee McFarling

The Food and Drug Administration should move more quickly to ensure pulse oximeters — the ubiquitous devices used to measure blood oxygen — work well in all patients, should better inform clinicians about the devices’ shortcomings in patients with darker skin, and should recall versions that are particularly problematic, patients, researchers, and consumer advocates testified during a public meeting on Friday.

The testimony occurred during an advisory panel meeting, held virtually to consider how to improve the safety of pulse oximeters, It comes more than three years after a study published at the height of the Covid-19 pandemic found that the devices didn’t detect low oxygen levels in some patients with darker skin, and after other studies showed the devices...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Medical Devices
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Opinion: RFK Jr. and MAHA should champion a Marshall Plan for obesity
Trump picks Johns Hopkins surgeon to head FDA: 10 things to know
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices
Will Trump's healthcare appointments bring 'radical changes'?

Share This Article